Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Monopar Therapeutics, Inc. (MNPR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$72.81+4.18%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MNPR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce net loss per share | A primary condition in Monopar Therapeutics, Inc.'s published investment case. The stated target is EPS loss less negative than -3.14 USD per share. | Improving | EPS loss worsens beyond -3.14 USD per share in FY27 | Diluted EPS: $-0.62 per share FY2026-Q2; GAAP. Published target: EPS loss less negative than -3.14 USD per share. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 12, 2026-0.62 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, clinical-stage biotechnology thesis, with potential progress tied to one key drug program. The multi-year view is on watch: management has made progress on regulatory steps, but the evidence snapshot rates recent performance as weak and overall confidence as low.
The evidence does not provide a valuation comparison or a clear account of what market expectations already assume, so whether MNPR looks cheap or expensive versus peers is unclear. No fragility gates fired, but that does not resolve the uncertainty around expectations.
Management says current funds should support operations through at least the end of 2027, and it has initiated a rolling regulatory submission for ALXN1840. Recent results include two reported earnings beats and one miss, while the snapshot still rates financial performance as weak and flags elevated near-term miss risk.
The multi-year thesis hinges on completing the regulatory submission and showing that ALXN1840’s reported clinical benefits support approval and commercialization. Near-term risks include a guidance cut or worsening employment data, while continued strength among healthcare peers could support sector momentum.
MNPR has a defined clinical and regulatory path, but the long-term thesis remains uncertain because financial performance is weak and risk is elevated. The key evidence to watch is progress toward approval and whether funding remains adequate through the stated period. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Extend operational funding through December 31, 2027 | Monopar is focused on developing cancer therapies and aims to extend funding through 2027. | Intact | funding not secured through 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Generate meaningful revenue from therapies | A supporting condition in Monopar Therapeutics, Inc.'s published investment case. The stated target is revenue exceeds $15.8 million. | Intact | revenue fails to exceed $15.8 million in FY27 | Revenue: $0 FY2026-Q2; GAAP. Published target: revenue exceeds $15.8 million. Target period ends 2027-12-31; this observation covers 2026-Q2. Aug 12, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.48 → $-2.46 · observed estimates
$0.02B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.48 | $15,549,419 | 7 / 7 |
| 2026-07-25 | $-3.48 | $15,549,419 | 7 / 7 |
| 2026-07-26 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-07-27 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-07-28 | $-3.13 | $15,840,750 | 8 / 9 |
| 2026-07-29 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-07-30 | $-3.13 | $15,840,750 | 8 / 9 |
| 2026-07-31 | $-3.13 | $15,840,750 | 8 / 9 |
| 2026-08-01 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-08-02 | $-3.13 | $15,840,750 | 8 / 9 |
| 2026-08-03 | $-3.13 | $15,840,750 | 8 / 9 |
| 2026-08-04 | $-3.13 | $15,840,750 | 8 / 9 |
| 2026-08-05 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-08-06 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-08-07 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-08-08 | $-3.13 | $15,840,750 | 8 / 9 |
| 2026-08-09 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-08-10 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-08-12 | $-3.13 | $15,840,750 | 8 / 9 |
| 2026-08-13 | $-3.13 | $15,840,750 | 8 / 9 |
| 2026-08-14 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-08-15 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-08-16 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-08-17 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-08-18 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-08-19 | $-3.48 | $15,594,530 | 7 / 7 |
| 2026-08-20 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-08-21 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-08-22 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-08-23 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-08-24 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-08-25 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-08-26 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-08-27 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-08-28 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-08-29 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-08-30 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-08-31 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-09-01 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-09-02 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-09-03 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-09-04 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-09-05 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-09-06 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-09-07 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-09-08 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-09-09 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-09-10 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-09-11 | $-2.51 | $27,902,848 | 7 / 7 |
| 2026-09-12 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-13 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-14 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-15 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-16 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-17 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-18 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-19 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-20 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-21 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-22 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-23 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-24 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-25 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-26 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-27 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-28 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-29 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-09-30 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-01 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-02 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-03 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-04 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-05 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-06 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-07 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-08 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-09 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-10 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-11 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-12 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-13 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-14 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-15 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-16 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-17 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-18 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-19 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-20 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-21 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-22 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-23 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-24 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-25 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-26 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-27 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-28 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-29 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-30 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-10-31 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-11-01 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-11-02 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-11-03 | $-2.46 | $27,902,848 | 7 / 7 |
| 2026-11-04 | $-2.46 | $27,902,848 | 7 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 11 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.